RETATRUTIDE EXPLAINED / SOURCE INDEX
The retatrutide story contains several kinds of evidence: discovery experiments, early human research and later clinical trials. This focused index follows the original papers cited in the explainer, rather than mixing them with unrelated peptide studies.
Keep the experimental model, population and time point attached to each result. A published phase 3 trial and a regulatory approval are different events. Official status information and trial-registry links remain in the relevant guide’s bibliography.
5 distinct original-paper links cited across 3 guides in this edition. Each link is counted once, even when several articles cite it.
Showing 5 of 5 original-paper links.
pubmed.ncbi.nlm.nih.gov
Open the original paper (opens in a new tab)WHY THIS SOURCE IS HERE
Understand what retatrutide is, how its receptor targets differ, and where mechanism ends and clinical evidence begins.
New England Journal of Medicine
What was observed
The highest studied arm had mean weight change of −17.5% at the primary 24-week endpoint versus −1.6% with placebo. At the secondary 48-week endpoint, changes were −24.2% versus −2.1%. Gastrointestinal events and increases in heart rate were reported.
Keep in view
This phase 2 result estimates effects in the studied arms and population, not an approved indication or a long-term cardiovascular outcome. The frequently quoted 24.2% is a secondary 48-week result, not the primary endpoint. Funded by Eli Lilly.
WHY THIS SOURCE IS HERE
Understand what retatrutide is, how its receptor targets differ, and where mechanism ends and clinical evidence begins.
Read the retatrutide results by population, endpoint, time point and estimand instead of comparing isolated headline percentages.
pubmed.ncbi.nlm.nih.gov
Open the original paper (opens in a new tab)WHY THIS SOURCE IS HERE
Understand what retatrutide is, how its receptor targets differ, and where mechanism ends and clinical evidence begins.
Read the retatrutide results by population, endpoint, time point and estimand instead of comparing isolated headline percentages.
Understand current regulatory status, what a clinical-trial listing means and how to read official participation information.
pubmed.ncbi.nlm.nih.gov
Open the original paper (opens in a new tab)WHY THIS SOURCE IS HERE
Read the retatrutide results by population, endpoint, time point and estimand instead of comparing isolated headline percentages.
Understand current regulatory status, what a clinical-trial listing means and how to read official participation information.
pubmed.ncbi.nlm.nih.gov
Open the original paper (opens in a new tab)WHY THIS SOURCE IS HERE
Read the retatrutide results by population, endpoint, time point and estimand instead of comparing isolated headline percentages.
Explore PepTup Europe and Echo Peptides, the research-material brands connected to this publication. Echo’s public study hub is one of our editorial sources; original papers are linked separately.
These are commercial relationships. A paper about a molecule does not validate a supplier’s product or establish suitability for human use.